The Global Alliance for iPSC Therapies (GAiT)
Breaching silos to advance iPSC therapies
The Global Alliance for induced Pluripotent Stem Cell Therapies (GAiT) supports the implementation and clinical application of therapies derived from induced pluripotent stem cells to the benefit of patients globally.
Cell and Gene Therapy Catapult (UK) 
INSERM (France) 
The New York Stem Cell Foundation (USA) 
University of Hong Kong (Hong Kong) 
Korean HLA-typed iPSC Banking Initiative (Korea) 
Center for Commercialisation of Regenerative Medicine (Canada)
GAiT activity is funded by a global consortium of organisations: the New York Stem Cell Foundation (New York, USA), the Cell and Gene Therapy Catapult (London, UK) the Centre for Commercialization of Regenerative Medicine (Toronto, Canada), the Korean HLA-Typed iPSC Banking Initiative (Seoul, Korea), the French Institute of Health and Medical Research INSERM (Paris, France), and the University of Hong Kong (Hong Kong, Hong Kong).
More information on GAiT is available in this recently published open access article here.
GAiT’s mission
GAiT serves as a central, international resource for those organisations who are developing therapies from clinical-grade induced pluripotent stem cells and to support the expansion of this nascent field.
With the support of its international partners, GAiT already has an early position on manufacturing, regulatory and quality standards, and GAiT’s intention is to support the delivery of the next generation of cell therapies.
More information on GAiT mission is available here.
GAiT (Global Alliance for iPSC Therapies)
Scottish Office
The Jack Copland Centre
52 Research Avenue North
Heriot-Watt Research Park
Edinburgh
EH14 4BE
UK.
